0001437749-23-005972 8-K 15 20230309 2.02 9.01 20230309 20230309 SAFEGUARD SCIENTIFICS INC 0000086115 6799 231609753 PA 1231 8-K 34 001-05620 23719961 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 610 293 0600 150 NORTH RADNOR-CHESTER ROAD SUITE F-200 RADNOR PA 19087 SAFEGUARD INDUSTRIES INC 19810525 SAFEGUARD CORP 19690521 8-K 1 sfe20230308_8k.htm FORM 8-K sfe20230308_8k.htm
false 0000086115 0000086115 2023-03-09 2023-03-09
 


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): March 9, 2023
 
Safeguard Scientifics, Inc.
(Exact Name of registrant as Specified in Charter)
 
 
Pennsylvania
1-5620
23-1609753
(State or other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer ID No.)
 
150 N. Radnor Chester Rd., STE F-200
Radnor, PA
19087
(Address of Principal Executive Offices)
(Zip Code)
 
Registrant’s telephone number, including area code: 610-293-0600
 
Not applicable 
 

(Former Name or Former Address if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock ($.10 par value)
SFE
The NASDAQ Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 
 

 
 
ITEM 2.02.         Results of Operations and Financial Condition.
 
On March 9, 2023 Safeguard Scientifics, Inc. (the “Company”) issued a press release setting forth the Company’s financial information for the three months and year ended December 31, 2022. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference.
 
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
ITEM 9.01.         Financial Statements and Exhibits.
 
(d)
Exhibits.
 
99.1
104
Cover Page Interactive Data File (formatted as Inline XBRL).
 
2

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Safeguard Scientifics, Inc.
 
       
       
Date: March 9, 2023
/s/ G. Matthew Barnard
   
 
Name: G. Matthew Barnard
 
 
Title:   General Counsel
 
 
3
 
EX-99.1 2 ex_485968.htm EXHIBIT 99.1 ex_485968.htm

Exhibit 99.1

 

a01.jpg

 

SAFEGUARD SCIENTIFICS ANNOUNCES FOURTH QUARTER AND YEAR END 2022 FINANCIAL RESULTS

 

 

Conference call and webcast on March 9, 2023 at 5 p.m. ET

 

 

Radnor, PA, March 9, 2023Safeguard Scientifics, Inc. (NASDAQ: SFE) (“Safeguard” or the “Company”) today announced financial results for the three months and year ended December 31, 2022.

 

2022 HIGHLIGHTS

 

 

Exits & Deployments

 

o

During the fourth quarter, Safeguard funded convertible loans of $0.5 million to meQuilibrium and $0.1 million from its subordinated line of credit to Trice Medical. Safeguard also funded an additional $0.25 million to Trice subsequent to the year-end pursuant to the same arrangement.

 

o

Safeguard’s annual deployments totaled $5.7 million, as compared to the full year 2022 estimated deployments of $5 million to $9 million.

 

 

Safeguard Company Performance

 

o

The aggregate trailing twelve-month revenues ending September 30, 2022 for eight of Safeguard’s companies, which excludes Other Ownership Interests, was $141 million, an increase of 8.7% from the comparable prior period.

 

o

Safeguard’s 1.3 million shares of Bright Health Group declined $0.5 million in value during the fourth quarter and $3.7 million for the 2022 annual period, resulting in a year-end value of $0.9 million.

 

 

Capital Return

 

o

During the fourth quarter, Safeguard repurchased 257,946 shares on the open market for $0.9 million at an average price of $3.41 per share.

 

o

For the year ended December 31, 2022, Safeguard repurchased 711,481 shares on the open market for $2.9 million at an average price of $4.13 per share under a previously authorized $3 million share repurchase plan.

 

o

In January 2023, the remaining amount authorized under the $3 million plan was purchased through open market transactions resulting in an aggregate of 736,577 shares being repurchased at an average price of $4.09 per share from March 2022 through January 2023.

 

 

Financial Results

 

o

Cash, cash equivalents, restricted cash and marketable securities totaled $19.3 million at December 31, 2022.

 

o

The carrying value of the Company’s ownership interests totaled $15.4 million at December 31, 2022.

 

o

Net loss for the three months ended December 31, 2022 was $4.9 million, or $0.30 per share, compared with a net loss of $8.6 million, or $0.51 per share, for the same period in 2021.

 

o

Net loss for the year ended December 31, 2022 was $14.3 million, or $0.87 per share, compared with net income of $27.0 million, or $1.36 per share, for the same period of 2021.

 

 

Operating Costs

 

o

Safeguard continued to reduce its operating costs. General and administrative expenses totaled $1.0 million for the fourth quarter as compared to $1.1 million for the comparable quarter of 2021. General and administrative expenses totaled $4.8 million and $7.2 million for the years ended December 31, 2022 and 2021, respectively, a 33% annual decline.

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 1 of 7

 

 

 

a01.jpg

 

 

o

Safeguard also continued to lower its corporate expenses1, which totaled $0.7 million for the fourth quarter of 2022, as compared to $0.8 million for the comparable period of 2021, a 12.5% decline. Corporate expenses totaled $3.2 million and $3.9 million for the years ended December 31, 2022 and 2021, respectively, a 17.9% annual decline.

 

 

Outlook

 

o

Safeguard expects follow-on deployments for its remaining ownership interests for 2023 to be in a range of $4 million to $6 million.

 

o

Safeguard expects to continue to closely manage corporate expenses in 2023 and has established a target of $3.0 to $3.2 million for the year, which continue to be exclusive of severance or transaction related expenses.

 

“The deteriorating business and capital raising environment noted last quarter has continued to impact many of Safeguard’s companies, with some lagging their operating plans and others experiencing liquidity challenges. While we are continuing to support our companies, we are considering additional actions to either participate in financing transactions that we view as opportunistic and attractive or, to be significantly diluted by those transactions if completed without our participation. We also continue to work with our financial advisor Houlihan Lokey as we evaluate strategic transactions for Safeguard that could yield greater value to our shareholders than an orderly run-off of the portfolio. In all cases, we remain committed to seeking a path that maximizes shareholder value.” said Eric C. Salzman, Chief Executive Officer.

 

 


1 Corporate expenses are general and administrative expenses excluding depreciation, severance, stock-based compensation and other non-recurring items.  See full reconciliation in the financial section of this statement.

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 2 of 7

 

 

 

 

a01.jpg

 

OWNERSHIP INTERESTS AT DECEMBER 31, 2022

 

Companies

Category

Acquisition Year

 

Primary

Ownership%

   

Fully Diluted

Ownership%

**

   

Carrying

Value

(in millions)

   

Cost

(in millions)

 
                                     
                                     
                                     
 

Revenue of $5 million to $10 million

 

Moxe

Healthcare

2016

    19.3 %     18.2 %     7.2       7.5  
 

Revenue of $10 million to $20 million

 

Clutch Holdings, Inc.

Digital Media

2013

    41.7 %     33.3 %     3.0       18.3  

InfoBionic, Inc.

Healthcare

2014

    25.2 %     22.1 %     -       22.0  

meQuilibrium

Healthcare

2015

    31.3 %     22.1 %     -       14.5  

Syapse, Inc.

Healthcare

2014

    11.0 %     8.6 %     1.5       26.6  
 

Revenue of $20 million to $30 million

 

Aktana, Inc.

Healthcare

2016

    13.6 %     11.5 %     -       15.9  

Prognos Health, Inc.

Healthcare

2011

    28.4 %     24.3 %     1.5       14.6  

Trice Medical +

Healthcare

2014

    11.6 %     8.6 %     -       12.0  
 

Other Ownership Interests

 

Bright Health Group

Healthcare

2021

                    0.9       -  

All others

Various

                    1.3       19.7  
               

TOTAL:

    $ 15.4     $ 151.1  

 

 

+ Carrying value does not include amounts representing our share of the entities’ losses which were funded subsequent to the quarter and are reflected in Accrued expenses.

 

** Based on information provided by each respective company. Assumes the conversion or exercise of all currently outstanding securities including the issuance of all shares available under authorized employee equity programs. Does not reflect liquidation preferences, priority payments, proceeds from option and/or warrant exercises or other company-specific transaction-related obligations in a liquidation or exit transaction.

 

 

CONFERENCE CALL AND WEBCAST DETAILS

 

Please call 10-15 minutes prior to the call to register.

 

Date: March 9, 2023

 

Time: 5:00 p.m. ET

 

Webcast: https://www.webcast-eqs.com/register/safeguardscientifics032023_en/en

 

Live Number: 877-407-1878

 

Speakers: Chief Executive Officer, Eric C. Salzman; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

 

Format: Discussion of the quarter’s financial results followed by Q&A

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 3 of 7

 

 

 

a01.jpg

 

The replay will be available at Safeguard.com’s investor relations site under “Past events”. For more information, please contact IR@safeguard.com. 

 

About Safeguard Scientifics

Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. Safeguard is currently pursuing a focused strategy to value-maximize and monetize its ownership interests over a multi-year time frame to drive shareholder value. For more information, please visit www.safeguard.com.

 

Forward-Looking Statements

Except for the historical information and discussions contained herein, statements contained in this release may constitute forward-looking statements within the meaning of the federal securities laws. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguards ability to maximize the value of monetization opportunities of its ownership interests and drive total shareholder returns, Safeguards initiatives, including, without limitation, taken or contemplated to enhance and unlock value for all of its shareholders, Safeguards efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguards ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguards management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguards strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguards projections regarding the reduction in its ongoing operating expenses, Safeguards projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our companies may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of our publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which our companies operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond our ability to predict or control. As a result of these and other factors, the Companys past operational and financial performance should not be relied on as an indication of future performance. Further information on the above risk factors and other potential factors that could affect our future business, operating results and financial condition is included in our Annual Report on Form 10-K for the year ended December 31, 2021 and other periodic filings with the Securities and Exchange Commission, including risks under the heading Risk Factors. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

 

###

 

SAFEGUARD CONTACT:

Mark Herndon

Chief Financial Officer

(610) 975-4913

mherndon@safeguard.com

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 4 of 7

 

 

 

 

a01.jpg

 

 

Safeguard Scientifics, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

 

   

December 31, 2022

   

December 31, 2021

 

Assets

               

Cash, cash equivalents, restricted cash and marketable securities

  $ 19,312     $ 24,764  

Ownership interests

    860       4,549  

Other current assets

    1,251       965  

Total current assets

    21,423       30,278  

Ownership interests in and advances

    14,545       21,972  

Other assets

    1,724       1,778  

Total Assets

  $ 37,692     $ 54,028  
                 

Liabilities and Equity

               

Other current liabilities

  $ 1,817     $ 1,734  

Total current liabilities

    1,817       1,734  

Lease liability - non-current

    1,249       1,678  

Other long-term liabilities

    50       50  

Total equity

    34,576       50,566  

Total Liabilities and Equity

  $ 37,692     $ 54,028  

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 5 of 7

 

 

 

 

a01.jpg

 

 

Safeguard Scientifics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

 

   

Three Months Ended

   

Twelve Months Ended

 
   

December 31,

   

December 31,

 
   

2022

   

2021

   

2022

   

2021

 

Operating expenses

  $ 1,035     $ 1,135     $ 4,775     $ 7,153  

Operating loss

    (1,035

)

    (1,135

)

    (4,775

)

    (7,153

)

Other income (loss), net

    (318

)

    (5,992

)

    (3,297

)

    22,035  

Interest, net

    318       79       794       276  

Equity income (loss), net

    (3,838

)

    (1,586

)

    (6,985

)

    11,846  

Net income (loss) before income taxes

    (4,873

)

    (8,634

)

    (14,263

)

    27,004  

Income tax benefit (expense)

                       

Net income (loss)

  $ (4,873

)

  $ (8,634

)

  $ (14,263

)

  $ 27,004  

Net income (loss) per share:

                               

Basic

  $ (0.30

)

  $ (0.51

)

  $ (0.87

)

  $ 1.36  

Diluted

  $ (0.30

)

  $ (0.51

)

  $ (0.87

)

  $ 1.36  

Weighted average shares used in computing income (loss) per share:

                               

Basic

    16,134       16,798       16,337       19,827  

Diluted

    16,134       16,798       16,337       19,827  

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 6 of 7

 

 

 

 

a01.jpg

 

 

Safeguard Scientifics, Inc.

Financial Data

(in thousands)

 

Additional Financial Information

 

Non-GAAP Measures

 

In discussing financial results and guidance, the Company refers to the measure "corporate expenses" which is not in accordance with Generally Accepted Accounting Principles (GAAP). We use this non-GAAP financial measure internally to make operating and strategic decisions, including evaluating our overall performance and as a factor in determining compensation for certain employees. We have defined corporate expenses as general and administrative costs excluding stock based compensation, severance costs, and non-recurring items and other.  Non-recurring items and other includes accruals related to the Company's LTIP plan that will not be paid until reaching a specified threshold within that plan as well as costs incurred for exploring strategic alternatives. We believe presenting this non-GAAP financial measure provides additional information to facilitate comparison of our historical operating costs and their trends and provides additional transparency on how we evaluate our cost structure. We also believe presenting this measure allows investors to view our performance using the same measure that we use in evaluating our performance and trends.

 

Corporate expenses reconciliation:

 

   

Three Months Ended

   

Twelve Months Ended

 
   

December 31,

   

December 31,

 
   

2022

   

2021

   

2022

   

2021

 

Corporate expenses

  $ 722     $ 825     $ 3,172     $ 3,865  

Stock based compensation

    309       310       1,445       1,779  

Severance costs

                      774  

Non-recurring items and other

    4             158       735  

General and administrative expenses

  $ 1,035     $ 1,135     $ 4,775     $ 7,153  

 

 

www.safeguard.com © 2023 Safeguard Scientifics, Inc. All rights reserved. 7 of 7

 

 
EX-101.SCH 3 sfe-20230309.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 sfe-20230309_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 sfe-20230309_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 sfe-20230309_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 a01.jpg begin 644 a01.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information
Mar. 09, 2023
Document Information [Line Items]  
Entity, Registrant Name Safeguard Scientifics, Inc.
Document, Type 8-K
Document, Period End Date Mar. 09, 2023
Entity, Incorporation, State or Country Code PA
Entity, File Number 1-5620
Entity, Tax Identification Number 23-1609753
Entity, Address, Address Line One 150 N. Radnor Chester Rd., STE F-200
Entity, Address, City or Town Radnor
Entity, Address, State or Province PA
Entity, Address, Postal Zip Code 19087
City Area Code 610
Local Phone Number 293-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol SFE
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000086115
XML 9 sfe20230308_8k_htm.xml IDEA: XBRL DOCUMENT 0000086115 2023-03-09 2023-03-09 false 0000086115 8-K 2023-03-09 Safeguard Scientifics, Inc. PA 1-5620 23-1609753 150 N. Radnor Chester Rd., STE F-200 Radnor PA 19087 610 293-0600 false false false false Common Stock SFE NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sfe.com/20230309/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports sfe20230308_8k.htm ex_485968.htm sfe-20230309.xsd sfe-20230309_def.xml sfe-20230309_lab.xml sfe-20230309_pre.xml http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sfe20230308_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "sfe-20230309_def.xml" ] }, "inline": { "local": [ "sfe20230308_8k.htm" ] }, "labelLink": { "local": [ "sfe-20230309_lab.xml" ] }, "presentationLink": { "local": [ "sfe-20230309_pre.xml" ] }, "schema": { "local": [ "sfe-20230309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sfe", "nsuri": "http://www.sfe.com/20230309", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20230308_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.sfe.com/20230309/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "sfe20230308_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.sfe.com/20230309/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001437749-23-005972-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-005972-xbrl.zip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